Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor

Cancer Detection and Prevention

Volumn 32, Issue 4, 2009, Pages 329-335

  Abdel Aziz, Mohamed M ^a   Lotfy, Mahmoud ^b   El Kady, Ibrahim M ^b   Abozaid, Mostafa ^c  

^a MANSOURA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Area under curve variables; Carcinogenesis; CEA; Colorectal carcinoma; EGFR; Gastrointestinal cancer; Monoclonal antibodies; Mutant p53 protein; Tyrosine kinase activity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER GRADING; CLINICAL ARTICLE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTANT PROTEINS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 60749108080     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2005.10.006     Document Type: Article

References (64)

1. Augenlicht L.H. Cell and molecular biology of colon cancer. (1989), CRC, Boca Raton, FL
2. Gatta G., Faivre J., Capocaccia R., and Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 34 (1998) 2176-2183
3. Thiis-Evensen E., Hoff G.S., Sauar J., Majak B.M., and Vatn M.H. Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63-72 years. Gut 45 (1999) 834-839
4. Zhang Y.L., Zhang Z.S., Wu B.P., and Zhou D.Y. Early diagnosis for colorectal cancer in China. World J Gastroenterol 8 (2002) 21-25
5. Li S., Nie Z., Li N., Li J., Zhang P., Yang Z., et al. Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study. Chin Med J 116 (2003) 200-202
6. Repetto L., Venturino A., Fratino L., Serraino D., Troisi G., Gianni W., et al. Geriatric oncology: A clinical approach to the older patient with cancer. Eur J Cancer 39 (2003) 870-880
7. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
8. Fearon E.R., Cho K.R., Nigro J.M., Kern S.E., Simons J.W., Ruppert J.M., et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247 (1990) 49-56
9. Kinzler K.W., Nilbert M.C., Vogelstein B., Bryan T.M., Levy D.B., Smith K.J., et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251 (1991) 1366-1370
10. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329 (1993) 1318-1327
11. Luo J.-C., Neugut A.I., Garbowski G., Forde K.A., Treat M., Smith S., et al. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett 91 (1995) 235-240
12. Shim K.-S., Kim K.-H., Park P.-W., Lee S.-Y., Choi J.-H., Han W.-S., et al. Increased serum levels of mutant p53 proteins in patients with colorectal cancer. J Korean Med Sci 13 (1998) 44-48
13. Sandler B., Smirnoff P., Shani A., Idelevich E., Kaganski N., Pfefferman R., et al. The role of blood vessels of soluble 53 kDa protein and CEA in monitoring colon cancer patients. Anticancer Res 19 (1999) 4229-4233
14. Attallah A.M., Abdel-Aziz M.M., El-Sayed A.M., and Tabll A.A. Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Det Prev 27 (2003) 127-131
15. Zusman I., Sandler B., Gurevich P., Zusman R., Smirnoff P., Tendler Y., et al. Comparative study of the role of serum levels of p53 antigen and its tumor cell concentration in colon cancer detection. Hum Antibodies Hybridomas 7 (1996) 123-128
16. Zusman I. Gel fiberglass membranes for affinity chromatography columns and their application to cancer detection. J Chromatogr B Biomed Sci Appl 715 (1998) 297-306
17. Gold P., and Freedman S.O. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121 (1965) 439-462
18. Paxton R.J., Mooser G., Pande H., Lee T.D., and Shively J.E. Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin supergene family. Proc Natl Acad Sci USA 84 (1987) 920-924
19. Benchimol S., Fuks A., Jothy S., Beauchemin N., Shirota K., and Stanners C.P. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57 (1989) 327-334
20. Kouri M., Pyrhnen S., and Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 49 (1992) 78-85
21. Zhao X.Y., Yu S.Y., Da S.P., Bai L., Guo X.Z., Dai X.J., et al. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 4 (1998) 147-149
22. Marrelli D., Roviello F., DeStefano A., Farnetani M., Garosi L., Messano A., et al. Prognostic significance of CEA, CA19-9 and CA72-4 preoperative serum levels in gastric carcinoma. Oncology 57 (1999) 55-62
23. Ohuchi N., Takahashi K., Matoba N., Sato T., Taira Y., Sakai N., et al. Comparison of serum assays for TAG-72, CA19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 19 (1989) 242-248
24. Schlessinger J., and Ullrich A. Growth-factor signaling by receptor tyrosine kinase. Neuron 9 (1992) 383-391
25. Rajkumar T. Growth factors and growth factor receptors in cancer (Review). Curr Sci 81 5 (2001) 535-541
26. Yamazaki H., Kijima H., Ohnishi Y., Abe Y., Oshika Y., Tsuchida T., et al. Inhibition of tumor growth by ribozyme mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 90 (1998) 581-587
27. Luo J.-C., Zehab R., Anttila S., Ridanpaa M., Husgafvel-Pursiainen K., Vainio H., et al. Detection of serum p53 protein in lung cancer patients. J Occup Med 36 (1994) 155-160
28. Partanen R., Koskinen H., Oksa P., Hemminki K., Carney W., and Smith S. Serum oncoproteins in asbestosis patients. Clin Chem 41 (1995) 1844-1847
29. Osaki T., Mitsudomi T., Oyama T., Nakanishi R., and Yasumoto K. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 108 (1995) 157-162
30. Choi J.-H., Oh J.Y., Ryu S.K., Kim S.J., Lee N.Y., Kim Y.S., et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79 (1997) 1879-1883
31. Oh M.J., Choi J.-H., Kim I.H., Lee Y.H., Huh J.Y., Park Y.K., et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 6 (2000) 4760-4763
32. Fucini C., Tommasi S.M., Rosi S., Malatantis G., Cardona G., Panichi S., et al. Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, CA19-9 analysis and second look surgery. Dis Colon Rectum 30 (1987) 273-277
33. Guadagni F., Roselli M., Cosimelli M., Ferroni P., Spila A., Cavaliere F., et al. CA72-4 serum marker-a new tool in the management of carcinoma patients. Cancer Invest 13 (1995) 227-238
34. ASCO. Update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7,1997, by the American Society of Clinical Oncology. J Clin Oncol 16 (1998) 793-795
35. EGTM. Tumor markers in the gastrointestinal cancers-EGTM recommendations. European Group on the Tumor Markers. Anticancer Res (1999) 2811-2815
36. Carpelan-Holmström M., Louhimo J., Stenman U., Alfthan H., Järvinen H., and Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal cancer. Oncology 66 4 (2004) 296-302
37. Marchena J., Acosta M.A., Garcia-Anguiano F., Simpson H., and Cruz F. Use of the preoperative levels of CEA in patients with colorectal cancer. Hepatogastroenterology 50 52 (2003) 1017-1020
38. Duffy M.J., van Dalen A., Haglund C., Hansson L., Klapdor R., Lamerz R., et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 39 6 (2003) 718-727
39. Tabuchi Y., Nakamura T., Kuniyasu T., Ohno M., Usami M., and Kuroda Y. Immunohistochemical p53 protein expression in advanced colorectal cancer lesions: no association with prognostic variables or survival. Bull Health Sci Kobe 15 (1999) 27-34
40. Sugo H., Takamori S., Kojima K., Beppu T., and Futagawa S. The significance of p53 mutation as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today 29 (1999) 849-855
41. Bazan V., Migliavacca M., Zanna I., Tubiolo C., Corsale S., Calo V., et al. DNA ploidy S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol 128 (2002) 650-658
42. Tang R., Ko M.C., Wang J.Y., Changchien C.R., Chen H.H., Chen J.S., et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1 209 patients. Int J Cancer 94 6 (2001) 859-863
43. Lechpammer M., Lukac J., Lechpammer S., Kovacevic D., Loda M., and Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19 2 (2004) 114-120
44. Takeda A., Shimada H., Nakajima K., Yoshimura S., Suzuki T., Asano T., et al. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol 6 1 (2001) 45-49
45. Forslund A., Kressner U., Lindmark G., Inganas M., and Lundholm K. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Int J Oncol 19 3 (2001) 501-506
46. Broll R., Duchrow M., Oevermann E., Wellm C., Schwandner O., Schimmelpenning H., et al. p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis 16 1 (2001) 22-27
47. Hildebrandt M., Mapara M.Y., Korner I.J., Bargou R.C., Moldenhauer G., and Dorken B. Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. Exp Hematol 25 (1997) 57-65
48. Khazaie K., Schirrmacher V., and Lichtner R.B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12 (1993) 255-274
49. Baselga J., and Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29 (1994) 127-138
50. Witters L., Kumar R., Mandal M., Bennett C.F., Miraglia L., and Lipton A. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res Treat 53 (1999) 41-50
51. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M., et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug resistant cell line in vitro and in vivo. Int J Cancer 98 (2002) 310-315
52. Bradley S.J., Garfinkle G., Walker E., Salem R., Chen L.B., and Steele Jr. G. Increased expression of the epidermal growth factor receptor on human colon carcinoma cells. Arch Surg 121 11 (1986) 1242-1247
53. Ozawa S., Ueda M., Ando N., Abe O., and Shimizu N. Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast and stomach. Jpn J Cancer Res 79 11 (1988) 1201-1207
54. Giacomelli L., Gianni W., Belfiore C., Gandini O., Repetto L., Filippini A., et al. Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Clin Cancer Res 9 7 (2003) 2678-2682
55. Kopp R., Rothbauer E., Mueller E., Schildberg F.W., Jauch K.W., and Pfeiffer A. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis Colon Rectum 46 10 (2003) 1391-1399
56. Layfield L.J., Bernard P.S., and Goldstein N.S. Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma. J Surg Oncol 83 4 (2003) 227-231
57. Amador M.L., and Hidalgo M. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin Colorectal Cancer 4 1 (2004) 51-62
58. DiCarlo A., Mariano A., D'Alessandro V., Belli G., Romano G., and Macchia V. Evaluation of epidermal growth factor receptor, carcinoembryonic antigen and Lewis carbohydrate antigens in human colorectal and liver neoplasias. Oncol Rep 8 2 (2001) 387-392
59. Langlois N., Walker L.G., Smith I., Skinner L., Eremin O., and Heys S.D. Expression of growth factor receptors is not a prognostic indicator in young patients with colorectal cancer. J R Coll Surg Edinb 42 2 (1997) 98-101
60. Lim B.H., Soong R., Grieu F., Robbins P.D., House A.K., and Iacopetta B.J. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 69 3 (1996) 200-204
61. Allegra C.J., Paik S., Colangelo L.H., Parr A.L., Kirsch I., Kim G., et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes'B and C colon cancer: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol 21 2 (2003) 241-250
62. Paluszkiewicz P., Berbec H., Pawłowska-Wakowicz B., Cybulski M., and Paszkowska A. p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumors. Cancer Detect Prev 28 (2004) 252-259
63. Adrover E., Maestro M.L., Sanz-Casla M.T., del Barco V., Cerdán J., Fernández C., et al. Expression of high p53 levels in colorectal cancer: a favorable prognostic factor. Br J Cancer 81 1 (1999) 122-126
64. Nicholson R.I., Gee J.M.W., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 (2001) S9-S15